

THE AVISA GROUP

<b>PROJECT:</b>	<b>EVALUATE THE IMPACT OF THE DRUG ABUSE AND TREATMENT ACT OF 2000 THAT PERMITS OFFICE-BASED PHYSICIANS TO PRESCRIBE BUPRENORPHINE FOR THE TREATMENT OF SUBSTANCE ABUSE</b>
<b>DATE:</b>	Summer 2002 – Summer 2005
<b>CLIENT:</b>	Center for Substance Abuse Treatment
<b>RESULTS:</b>	<ul style="list-style-type: none"> <li>➤ Avisa formed a partnership with Westat, a major Washington, DC research and evaluation company, to respond to a highly publicized RFP issued by the Center for Substance Abuse Treatment (CSAT), a long-standing client of the Avisa Group.</li> <li>➤ The RFP response on which the Avisa Group and Westat collaborated highlighted the capabilities, experience and professional network of the Avisa Group in the area of substance abuse and the infrastructure and survey research capabilities of Westat.</li> <li>➤ Our team was ranked first and won the competitive bidding process.</li> <li>➤ Members of the Avisa Group share responsibility for the over-all evaluation design as well as for the economic and organized care system components of the evaluation.</li> <li>➤ At key points throughout the evaluation, the Avisa Group has suggested and implemented improved evaluation components to address unexpected issues that have emerged.</li> <li>➤ CSAT project officer has given high marks to performance of the Avisa – Westat team.</li> </ul>
<b>OUTCOME</b>	The partnership of the Avisa Group and Westat won the engagement and throughout the process the Avisa Group has provided additional intellectual and policy leadership for this evaluation, as well as providing key resources through its extensive professional network.